Nemolizumab

Atopic dermatitis (adults and paediatric patients 12 years of age and older): initial dose 60 mg (two 30 mg injections), followed by 30 mg given every 4 weeks; after 16 weeks of treatment, for patients who achieve clear or almost clear skin, a dosage of 30 mg every 8 weeks is recommended. For atopic dermatitis, use with topical corticosteroids and/or topical calcineurin inhibitors, and discontinue the topical therapies when the disease has sufficiently improved. Complete all age-appropriate vaccinations as recommended by current immunisation guidelines PRIOR to treatment; avoid live vaccines during treatment. For the initial dose, administer each of the two injections at different injection sites; alternate the injection site with each injection; do not inject into skin that is tender, inflamed, swollen, damaged, bruised, scarred or has open wounds. Missed dose: administer as soon as possible, then resume the regular schedule. Must be reconstituted before administration (single-dose prefilled dual-chamber pen); allow to reach room temperature 30-45 minutes; after reconstitution each pen delivers 30 mg/0.49 mL; use within 4 hours and discard unused reconstituted pens thereafter. Paediatric: safety and effectiveness have NOT been established in prurigo nodularis in any paediatric patient, nor in atopic dermatitis below 12 years of age; in patients 12 years and older administer by or under the supervision of a trained adult or caregiver. No numeric per-kg paediatric dose is stated in the source — verify paediatric use against a children's formulary. Not from a UK SPC — UK product information may differ.